XFOR logo

XFOR
X4 Pharmaceuticals Inc

3,530
Mkt Cap
$385.5M
Volume
231,982.00
52W High
$6.96
52W Low
$1.35
PE Ratio
-0.98
XFOR Fundamentals
Price
$4.07
Prev Close
$4.24
Open
$4.24
50D MA
$3.74
Beta
1.52
Avg. Volume
529,721.26
EPS (Annual)
-$1.87
P/B
2.07
Rev/Employee
$780,288.89
$7.34
Loading...
Loading...
News
all
press releases
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Moderate Buy" by Analysts
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the company, Marketbeat.com...
MarketBeat·16d ago
News Placeholder
More News
News Placeholder
X4 Pharmaceuticals (NASDAQ:XFOR) Raised to Hold at Wall Street Zen
Wall Street Zen raised shares of X4 Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·17d ago
News Placeholder
Q3 Earnings Forecast for XFOR Issued By Brookline Cap M
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Equities research analysts at Brookline Cap M issued their Q3 2026 earnings per share estimates for shares of X4 Pharmaceuticals in a research note issued on Tuesday, March 17th. Brookline Cap M analyst L. Cann anticipates that the company will...
MarketBeat·17d ago
News Placeholder
Research Analysts Set Expectations for XFOR Q1 Earnings
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Stock analysts at Brookline Cap M issued their Q1 2026 earnings per share estimates for shares of X4 Pharmaceuticals in a research report issued on Tuesday, March 17th. Brookline Cap M analyst L. Cann forecasts that the company will post earning...
MarketBeat·19d ago
News Placeholder
X4 Pharmaceuticals (NASDAQ:XFOR) Issues Quarterly Earnings Results
X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.36) by...
MarketBeat·19d ago
News Placeholder
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +38.89% and +53.22%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago
News Placeholder
X4 Pharmaceuticals (XFOR) Projected to Post Quarterly Earnings on Tuesday
X4 Pharmaceuticals (NASDAQ:XFOR) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 24. (View Earnings Report at...
MarketBeat·21d ago
News Placeholder
X4 Pharmaceuticals, Inc. $XFOR Shares Acquired by Kingdon Capital Management L.L.C.
Kingdon Capital Management L.L.C. increased its holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) by 300.0% in the third quarter, according to the company in its most recent Form 13F...
MarketBeat·21d ago
News Placeholder
Rosalind Advisors Inc. Makes New Investment in X4 Pharmaceuticals, Inc. $XFOR
Rosalind Advisors Inc. acquired a new stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) in the third quarter, according to its most recent filing with the Securities and...
MarketBeat·25d ago
News Placeholder
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
ProQR (PRQR) delivered earnings and revenue surprises of -12.50% and -36.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·25d ago
<
1
2
...
>

Latest XFOR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.